321 related articles for article (PubMed ID: 26779616)
21. [Radium-223 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) : The androgen receptor-independent active agent in the therapeutic sequence].
König F; Strauß A; Johannsen M; Mommsen C; Fricke E; Klier J; Mehl S; Pfister D; Sahlmann CO; Werner A; Goebell PJ
Urologe A; 2020 Jan; 59(1):53-64. PubMed ID: 31598745
[TBL] [Abstract][Full Text] [Related]
22. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
Poeppel TD; Handkiewicz-Junak D; Andreeff M; Becherer A; Bockisch A; Fricke E; Geworski L; Heinzel A; Krause BJ; Krause T; Mitterhauser M; Sonnenschein W; Bodei L; Delgado-Bolton RC; Gabriel M
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):824-845. PubMed ID: 29234845
[TBL] [Abstract][Full Text] [Related]
23. Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database.
Keizman D; Fosboel MO; Reichegger H; Peer A; Rosenbaum E; Desax MC; Neiman V; Petersen PM; Mueller J; Cathomas R; Gottfried M; Dresler H; Sarid D; Mermershtain W; Rouvinov K; Mortensen J; Gillessen S; Daugaard G; Omlin A
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):289-293. PubMed ID: 28244493
[TBL] [Abstract][Full Text] [Related]
24. Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.
Shirley M; McCormack PL
Drugs; 2014 Apr; 74(5):579-86. PubMed ID: 24610703
[TBL] [Abstract][Full Text] [Related]
25. Radium-223 in metastatic castration resistant prostate cancer.
Vuong W; Sartor O; Pal SK
Asian J Androl; 2014; 16(3):348-53. PubMed ID: 24713838
[TBL] [Abstract][Full Text] [Related]
26. Targeting bone metastases in prostate cancer: improving clinical outcome.
Body JJ; Casimiro S; Costa L
Nat Rev Urol; 2015 Jun; 12(6):340-56. PubMed ID: 26119830
[TBL] [Abstract][Full Text] [Related]
27. Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice.
Morgan SC
J Med Imaging Radiat Sci; 2019 Dec; 50(4S1):S26-S30. PubMed ID: 31231006
[TBL] [Abstract][Full Text] [Related]
28. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
[TBL] [Abstract][Full Text] [Related]
29. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
30. Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.
Yap KK; Wong W; Ji L; Groshen S; Quinn DI; Bryce AH; Dorff TB
Cancer Treat Res Commun; 2019; 18():100114. PubMed ID: 30529990
[TBL] [Abstract][Full Text] [Related]
31. Radium 223 for the treatment of metastatic castration-resistant prostate cancer.
Miranda J; Viñal D; Pinto Á
Arch Esp Urol; 2019 Jun; 72(5):500-507. PubMed ID: 31223127
[TBL] [Abstract][Full Text] [Related]
32. Bone-targeting radiopharmaceuticals including radium-223.
Brady D; Parker CC; O'Sullivan JM
Cancer J; 2013; 19(1):71-8. PubMed ID: 23337760
[TBL] [Abstract][Full Text] [Related]
33. [Targeted radionuclide therapy for castration-resistant prostate cancer].
Nakamura K; Ohga S; Sasaki T; Baba S; Honda H
Nihon Rinsho; 2014 Dec; 72(12):2181-5. PubMed ID: 25518355
[TBL] [Abstract][Full Text] [Related]
34. Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging.
Iizuka J
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():16-23. PubMed ID: 30489033
[TBL] [Abstract][Full Text] [Related]
35. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
Nilsson S
Expert Opin Drug Saf; 2015 Jul; 14(7):1127-36. PubMed ID: 26022669
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Matsubara N; Kinuya S; Hosono M; Yajima Y; Doi T
Int J Clin Oncol; 2017 Oct; 22(5):954-963. PubMed ID: 28478485
[TBL] [Abstract][Full Text] [Related]
37. Radium-223 in the therapeutic sequence of metastatic castration-resistant prostate cancer.
Unda-Urzaiz M; Sousa-Campo R; Rodríguez-Antolín A; Silva-Marins C; Juárez-Soto A; Miñana-López B; Figueiredo-de Castro A; Cozar-Olmos JM
Actas Urol Esp (Engl Ed); 2018 May; 42(4):227-237. PubMed ID: 28711312
[TBL] [Abstract][Full Text] [Related]
38. Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary.
O'Sullivan JM; Abramowitz E; Sierra-Scacalossi L
Future Oncol; 2023 May; 19(15):1021-1028. PubMed ID: 36942803
[TBL] [Abstract][Full Text] [Related]
39. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
40. Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.
Vogelzang NJ
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):809-819. PubMed ID: 28649893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
